Search

A recent study conducted by researchers from the University of Ottawa and The Ottawa Hospital explores the use of oral Janus kinase inhibitors (JAKi) in the treatment of moderate-to-severe atopic dermatitis (AD). The study highlights the potential off-target effects of JAKi and emphasizes the importance of laboratory monitoring to mitigate risks. The researchers provide best practice recommendations for assessing and monitoring key laboratory parameters, as well as suggestions for dose reduction or switching in response to laboratory changes. The study concludes that appropriate patient selection and laboratory assessment are crucial strategies when using oral JAKi to treat AD. [Extracted from the article]

A study conducted at Oregon Health & Science University (OHSU) investigated the efficacy and safety of bermekimab, a monoclonal antibody, in patients with moderate-to-severe atopic dermatitis (AD). Four phase 2 studies were conducted, but larger controlled studies did not confirm the initial positive results observed in earlier trials. The research concluded that while bermekimab showed potential as a treatment for AD in preclinical and early open-label trials, further research is needed to confirm its effectiveness. The study was funded by Janssen Pharmaceutical Companies of Johnson & Johnson. [Extracted from the article]

A recent report from Osaka University in Japan discusses the use of dupilumab, an anti-IL-4Ra antibody, as a therapeutic agent for atopic dermatitis (AD), a chronic eczematous skin disease. The study aimed to identify biomarkers and patient-related factors that could predict the effectiveness of dupilumab treatment. The researchers found that baseline biomarkers such as lactate dehydrogenase (LDH) and periostin, as well as clinical factors like comorbidity of food allergy and duration of severe disease, could be useful indicators for selecting dupilumab as a systemic treatment for AD. The research suggests that these factors can help predict the efficacy of dupilumab. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06585202, which is a Phase 2 open-label study investigating the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in participants with moderate to severe atopic dermatitis. The study will be conducted over a period of 12 weeks and aims to assess the incidence and severity of treatment emergent adverse events, as well as changes in Eczema Area and Severity Index (EASI) and other outcome measures. The trial is currently recruiting participants and is being conducted in the United States. [Extracted from the article]

A recent study from Oregon Health & Science University (OHSU) provides new insights into the use of oral JAK inhibitors for atopic dermatitis (AD). JAK inhibitors have shown promising efficacy in phase 3 trials and have a rapid onset of action. However, their use is not appropriate for all AD patients, and dermatologists should carefully consider their use. The study provides guidance on prescribing JAK inhibitors, including patient selection, dosing, monitoring, and long-term use. It also highlights the need for future studies to assess the safety and durability of JAK inhibitor use in AD patients. The decision to use JAK inhibitors should be made collaboratively between the patient and provider, taking into account disease severity and individual risk factors. [Extracted from the article]

A new report from Taipei Veterans General Hospital in Taiwan explores the association between atopic dermatitis (AD) and venous thromboembolism (VTE) in adults. The study, which included a total of 284,858 participants, found that adults with AD had a significantly increased risk of developing VTE compared to those without AD. The absolute risk difference, however, was small. The researchers suggest that adults with AD who present with symptoms suggestive of VTE should undergo cardiovascular examination and management. Further research is needed to understand the underlying pathophysiology of the association between AD and VTE. [Extracted from the article]

A recent study conducted by Bahcesehir University Faculty of Medicine in Turkey examined the ocular surfaces of children with atopic dermatitis (AD). The study found that pediatric patients with AD may experience significant changes in conjunctival histopathology, which can be detected through tests measuring tear film. The majority of children with AD were shown to have dry eye. These findings provide valuable insights into the ocular manifestations of AD in children. [Extracted from the article]

A recent study conducted by researchers at the University of Indonesia has found that probiotic supplementation can significantly decrease the severity of atopic dermatitis (AD) in adults, thereby improving their overall quality of life. AD is a chronic skin disease characterized by abnormal skin barrier function and heightened immunologic sensitization. The study suggests that probiotics may offer potential therapeutic benefits in managing this condition and improving the quality of life for adult AD patients. The research was conducted using a systematic review and meta-analysis of randomized controlled trials. [Extracted from the article]

The article reviews the role of nemolizumab in treating moderate-to-severe atopic dermatitis in adults, highlighting its potential efficacy and safety. Topics discussed include ongoing clinical trials, common adverse effects such as nasopharyngitis, and the overall promise of nemolizumab as a treatment option.

The article reviews the Eczema Area and Severity Index (EASI) after 20 years of use, highlighting its validation and current challenges in measuring atopic dermatitis. Topics discussed include its performance across various severities, validation gaps especially in diverse populations, and the potential of technological adaptations for remote assessments.

A report from Sungkyunkwan University School of Medicine in Seoul, South Korea discusses the development of atopic dermatitis (AD) and food allergies (FA) in infants. The research highlights the multifactorial nature of AD and FA, involving genetic susceptibility, skin-barrier dysfunction, microbiome alterations, and immune dysregulation. The study suggests that reliable biomarkers are needed to identify high-risk individuals for more effective preventive strategies. The researchers propose using a non-invasive technique called skin tape stripping (STS) to analyze the stratum corneum and gain insights into the early pathogenesis and potential progression of AD and FA. [Extracted from the article]

A recent study conducted at University Hospital Schleswig Holstein in Lubeck, Germany, has found that atopic dermatitis (AD), a chronic inflammatory skin disease, is associated with an increased risk of cardiovascular diseases (CVDs). The study analyzed data from electronic health records of over 1 million patients with AD and found that patients with AD had a significantly higher risk for 53 different cardiovascular diagnoses, including heart failure, venous thromboembolism, and major adverse cardiovascular events. The study highlights the importance of monitoring and managing cardiovascular health in patients with AD. [Extracted from the article]

The article reviews the effectiveness of hydrocortisone ointment in treating atopic dermatitis, highlighting its benefits and comparing it with potential alternatives. Topics include the chronic nature of atopic dermatitis, the role of environmental and genetic factors, and the efficacy of various treatment options like human breast milk and tacrolimus.

The article discusses recent research from Yale University on the local tolerability of topical roflumilast in treating seborrheic dermatitis, psoriasis, and atopic dermatitis. Topics discussed include the importance of minimizing skin irritation for patient adherence, the favorable tolerability results observed in Phase 3 trials, and the effectiveness of roflumilast formulations in sensitive skin areas.

The article offers information on the use of hydrogels as a promising treatment platform for inflammatory skin diseases. Topics discussed include the mechanisms of hydrogel design and drug integration; their effectiveness and safety in clinical trials for conditions like psoriasis and atopic dermatitis; and future challenges and opportunities in improving hydrogel-based therapies.

A study conducted by researchers at Cukurova University Faculty of Medicine in Turkey has found that refraining from consuming allergic foods, chronic inflammation, and the use of immunosuppressive drugs are factors associated with anemia in children with atopic dermatitis (AD). The study analyzed the medical records of 100 children with AD and 100 healthy children of the same age group without AD. The frequency of AD was significantly higher in children with AD compared to healthy children. The researchers suggest that clinicians should be aware of screening and monitoring for AD in children with AD to minimize the burden of the disease. Further studies are needed to investigate the link between iron deficiency anemia and AD. [Extracted from the article]

A report from the Indiana University School of Medicine discusses research findings on the mechanisms for the initiation of food allergies in individuals with atopic dermatitis. The study focuses on a mouse model with skin barrier mutations and explores how exposure to allergens and detergents can lead to the development of food allergies. The research suggests that early oral exposure to allergenic foods before skin sensitization may induce tolerance to food allergens and protect against the development of food allergies. The study also highlights the impact of maternal atopy and skin barrier function on the development of food allergies. [Extracted from the article]

A recent study conducted by researchers at Kyungpook National University in South Korea aimed to assess the association between long-term use of oral corticosteroids and adverse events (AEs) in adult patients with atopic dermatitis (AD). The study used data from the Health Insurance Review and Assessment Service database of South Korea and included 1,025,270 patients with AD. The results showed that there was no increased risk of AEs with the use of oral corticosteroids for more than 30 days, but a slightly higher risk was observed with use for more than 90 days. The researchers concluded that further research is needed to fully understand these findings. [Extracted from the article]

A new study conducted at Yale University has evaluated the long-term safety of upadacitinib, a medication used to treat moderate-to-severe atopic dermatitis (AD). The study analyzed data from three ongoing Phase 3 trials and included over 7000 patient-years of exposure. The results showed that rates of adverse events of special interest remained low throughout the 5-year treatment period, indicating a favorable benefit-risk profile for upadacitinib in the treatment of adults and adolescents with AD. The study provides valuable information for individuals seeking long-term treatment options for this chronic skin condition. [Extracted from the article]

A recent study found that long-term use of oral corticosteroids for individuals with atopic dermatitis may be associated with a small increased risk of adverse outcomes. The study suggests that healthcare professionals should carefully consider the benefits of oral corticosteroids against the observed small risk of adverse events, while continuously monitoring for any adverse effects. Further research is needed to confirm these findings. The study provides contact information for the corresponding authors and a link to access the full study. [Extracted from the article]

A recent study conducted at Charite University Hospital and School of Medicine in Berlin, Germany, explored the effects of short-term heat application on itch intensity in patients with atopic dermatitis (AD). The study consisted of two parts: a controlled trial examining the impact of brief heat treatment on mechanically induced itch, and a real-life study of AD patients experiencing itch attacks. The results showed a significant and immediate reduction in itch sensations following heat application, with effects lasting over time. However, individual responses varied, highlighting the potential for personalized approaches in AD treatment. The researchers suggest further research in larger cohorts to refine treatment protocols and deepen understanding of the mechanisms involved. [Extracted from the article]

A clinical trial has been launched to study the sleep and scratching behavior in adolescents and adults with atopic dermatitis and adults with psoriasis. Pruritis, or itching, is a common symptom in these patients and can negatively impact their quality of life. The study aims to develop and validate a wrist-based solution to quantify nocturnal scratching using multiple technologies such as polysomnography, video capture, and wrist sensors. The trial is currently recruiting participants and is expected to be completed by June 2026. [Extracted from the article]

A systematic review conducted by researchers at Queen's University in Canada examined the response to biologic therapy in individuals with moderate-to-severe psoriasis and atopic dermatitis, specifically focusing on participants with skin of color (SOC). The review analyzed 11 studies with a total of 1,781 SOC participants. While no significant differences in treatment outcomes were found among the SOC population, variations in baseline characteristics and comorbidities were observed, suggesting that race or ethnic background should be considered when prescribing treatment for psoriasis or atopic dermatitis. The researchers recommend further large-scale randomized controlled trials to confirm these findings. [Extracted from the article]

A study conducted by Menoufia University explores the potential link between atopic dermatitis (AD) and irritable bowel syndrome (IBS). The research suggests that IBS patients are more likely to suffer from skin conditions such as atopic dermatitis compared to healthy individuals. Both atopic dermatitis and IBS are believed to be caused by immune dysregulation in genetically susceptible individuals. The study involved 140 participants, with 70 diagnosed with IBS and 70 healthy controls. The findings indicate a strong link and possible common pathological pathways between AD and IBS. [Extracted from the article]

A recent study conducted by Oregon Health & Science University (OHSU) has found that upadacitinib, an oral selective Janus kinase inhibitor, rapidly improves patient-reported outcomes (PROs) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The study analyzed data from 1683 patients and found that a greater proportion of patients receiving upadacitinib experienced improvements in itch, skin pain and symptom severity, sleep, daily activities, quality of life, mental health, and patient impressions of disease severity and treatment compared to those receiving a placebo. The improvements were sustained over a 16-week period. This research provides valuable insights into the effectiveness of upadacitinib as a monotherapy for AD. [Extracted from the article]

A clinical trial, NCT06390878, is being conducted to investigate the effects of rewilding kindergarten yards on children's health. The trial aims to determine if rewilding, which involves adding vegetation and playground equipment to the yards, can increase the diversity of health-associated microbiota and reduce the prevalence of allergies, asthma, atopic dermatitis, and infections. Additionally, the trial will assess if rewilding has positive effects on cognitive skills and changes cortisol and plasma cytokine levels. The study will involve 320 children aged 1-5, with 120 of them undergoing more detailed analysis using microbiological and blood samples. The goal of the study is to determine if rewilding can have beneficial effects on children's health. [Extracted from the article]

A recent study conducted at Yeouido St. Mary's Hospital in Korea analyzed data from 355,277 Korean patients diagnosed with atopic dermatitis (AD) between 2002 and 2019. The study found that the prevalence of AD increased from 3.88% in 2002 to 5.03% in 2019, with significant increases in the 12-19-year-old and 20 years or older age groups. The proportion of patients with moderate to severe AD also increased during this period. Surprisingly, the prescription pattern for AD treatment, which primarily relied on corticosteroids, did not change significantly despite the rising prevalence of moderate and severe cases. The study suggests a need for the development of novel treatment guidelines that prioritize biologics for enhanced safety and efficacy. [Extracted from the article]

A recent study conducted by researchers at the First Affiliated Hospital of Soochow University in Suzhou, China, focused on the treatment of psoriasiform dermatitis in patients with a history of malignancy. Psoriasis and atopic dermatitis are inflammatory skin disorders that can be challenging to diagnose and treat accurately, especially when their clinical and pathological features overlap. The study explored the use of biologic therapies, such as the selective Janus kinase 1 (JAK1) inhibitor abrocitinib and the oral phosphodiesterase (PDE)-4 inhibitor apremilast, in improving the condition of patients with psoriasiform dermatitis and a history of malignancy. The researchers found significant improvement in the patients' conditions after treatment with systemic glucocorticoid, abrocitinib, or apremilast. [Extracted from the article]

A study conducted by the University of West Attica in Athens, Greece, explores the potential benefits and limitations of using biotics in the treatment of various health conditions among children and adolescents. Biotics, such as probiotics, have shown promise in improving symptoms and outcomes in conditions such as infectious diarrhea, necrotizing enterocolitis, functional gastrointestinal diseases, and atopic dermatitis. However, further randomized, controlled clinical studies are needed to fully understand the effects of biotics in this population. The study emphasizes the unique characteristics of children and adolescents, including their rapid growth rates, high nutritional requirements, and susceptibility to infectious diseases. [Extracted from the article]

A recent study from King's College in London highlights the impact of more severe atopic dermatitis (AD) and psoriasis on quality of life, multimorbidity, and healthcare costs. The lack of reliable biomarkers for this at-risk group hinders proactive intervention. To address this, the BIOMAP consortium has curated clinical and molecular data from various sources to map disease severity instruments and measures. The study emphasizes the importance of considering biomarker purpose, clinical context, and stage of development when analyzing datasets, as well as validating biomarker associations with disease severity outcomes. This research aims to provide clinically relevant and patient-centric insights for future efforts. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06277765, which aims to evaluate the efficacy and safety of CM310 in adolescent patients with moderate-to-severe atopic dermatitis. The trial is a multi-center, randomized, double-blind, placebo-controlled phase 3 study. The primary outcome measure is the proportion of subjects achieving EASI-75 at week 18, which assesses the severity of atopic dermatitis. The trial is not yet recruiting and is expected to be completed by May 30, 2025. The study is being conducted by Keymed Biosciences Co.Ltd in China. [Extracted from the article]

A recent report from Eastern Virginia Medical School explores the relationship between food allergies and atopic dermatitis, a type of skin inflammation. The research suggests that food allergies in individuals with atopic dermatitis are influenced by a combination of genetics, diet, environment, and the microbiome. When inflamed skin comes into contact with food antigens, contact hypersensitivity can occur, leading to systemic contact dermatitis. The study recommends identifying and avoiding food triggers and contact allergens as part of the treatment plan for dermatitis patients. The research has been peer-reviewed and can be accessed through the Clinical Reviews in Allergy & Immunology journal. [Extracted from the article]

A new report from George Washington University School of Medicine and Health Sciences discusses the efficacy and safety of Tapinarof cream 1% in the treatment of atopic dermatitis (AD). The cream was found to be effective and well-tolerated in adults and children as young as 2 years old with moderate to severe AD. The cream demonstrated statistically significant improvements in primary and secondary efficacy endpoints, including a reduction in symptoms and improvement in quality of life. Adverse events were mostly mild or moderate, and trial discontinuation rates were low. Overall, Tapinarof cream 1% shows promise as a treatment option for AD. [Extracted from the article]